Incyte (INCY *) Stock Overview

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. More details

INCY * fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	6/6
Financial Health	6/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (16.3x) is below the Biotechs industry average (26x)

Earnings grew by 6631.4% over the past year

Risk Analysis

Shares are highly illiquid

Earnings are forecast to decline by an average of 15.2% per year for the next 3 years

Significant insider selling over the past 3 months

INCY * Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW497,212 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

497,212 investors already sharing narratives

View all narratives

Incyte Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Incyte
Historical stock prices
Current Share Price	US$1,676.03
52 Week High	US$1,995.00
52 Week Low	US$1,500.00
Beta	0.76
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-4.14%
Change since IPO	-0.30%

Recent updates

Shareholder Returns

	INCY *	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how INCY * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how INCY * performed against the MX Market.

Price Volatility

Is INCY *'s price volatile compared to industry and market?
INCY * volatility
INCY * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: INCY *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine INCY *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1991	2,844	Bill Meury	www.incyte.com

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma.

Incyte Corporation Fundamentals Summary

How do Incyte's earnings and revenue compare to its market cap?
INCY * fundamental statistics
Market cap	Mex$408.02b
Earnings (TTM)	Mex$25.02b
Revenue (TTM)	Mex$93.69b

16.3x

P/E Ratio

4.4x

P/S Ratio

Is INCY * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INCY * income statement (TTM)
Revenue	US$5.36b
Cost of Revenue	US$2.53b
Gross Profit	US$2.83b
Other Expenses	US$1.40b
Earnings	US$1.43b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	7.17
Gross Margin	52.77%
Net Profit Margin	26.71%
Debt/Equity Ratio	0%

How did INCY * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/05 10:22
End of Day Share Price	2026/05/26 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Incyte Corporation is covered by 45 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jasper Hellweg	Argus Research Company
Thomas Russo	Baird
Peter Lawson	Barclays

Incyte (INCY *) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Incyte Corporation Competitors

United Therapeutics

Swedish Orphan Biovitrum

Genmab

Celltrion

Price History & Performance

Recent News & Updates

Incyte Corporation(NasdaqGS:INCY) dropped from Russell Midcap Growth Benchmark

Incyte Receives Positive Chmp Opinion for Opzelura (Ruxolitinib) Cream for Treatment of Moderate Atopic Dermatitis in Adults

Incyte Presents Results from Pivotal Phase 3 Frontmind Trial of Tafasitamab Combination At Eha 2026 Plenary

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire to acquire Vega Therapeutics, Inc. from Star Therapeutics, Inc. for $2 billion.

Incyte Announces Positive Results from Pivotal Phase 3 Frontmind Trial Evaluating Tafasitamab (Monjuvi/Minjuvi) and Lenalidomide Added to R-Chop Versus R-Chop Alone in Previously Untreated High-Risk Dlbcl and Hgbl

Principal Financial Officer recently sold Mex$3.5m worth of stock

Recent updates

Incyte Corporation(NasdaqGS:INCY) dropped from Russell Midcap Growth Benchmark

Incyte Receives Positive Chmp Opinion for Opzelura (Ruxolitinib) Cream for Treatment of Moderate Atopic Dermatitis in Adults

Incyte Presents Results from Pivotal Phase 3 Frontmind Trial of Tafasitamab Combination At Eha 2026 Plenary

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire to acquire Vega Therapeutics, Inc. from Star Therapeutics, Inc. for $2 billion.

Incyte Announces Positive Results from Pivotal Phase 3 Frontmind Trial Evaluating Tafasitamab (Monjuvi/Minjuvi) and Lenalidomide Added to R-Chop Versus R-Chop Alone in Previously Untreated High-Risk Dlbcl and Hgbl

Principal Financial Officer recently sold Mex$3.5m worth of stock

Insufficient new directors

Incyte Announces 24-Week Data For Opzelura Cream In Adults With Moderate Atopic Dermatitis

Incyte Announces Fda Approval of Jakafi Xr Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Incyte Corporation Reaffirms Earnings Guidance for the Fiscal Year 2026

Incyte Corporation, Annual General Meeting, Jun 08, 2026

First quarter 2026 earnings released: EPS: US$1.52 (vs US$0.82 in 1Q 2025)

Insufficient new directors

Incyte Highlights New Phase 3 Tafasitamab Data At the 2026 American Society of Clinical Oncology Annual Meeting

Incyte Announces New Positive 54-Week Data for Povorcitinib in Hidradenitis Suppurativa

Incyte Corporation Announces Executive Changes

Incyte Highlights Late-Breaking Hidradenitis Suppurativa Data And Features Ruxolitinib Cream And Povorcitinib At The American Academy Of Dermatology Annual Meeting

Incyte Announces European Commission Approval of Zynyz (Retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal

Full year 2025 earnings released: EPS: US$6.59 (vs US$0.16 in FY 2024)

Incyte Corporation Provides Earnings Guidance for the Fiscal Year 2026

Incyte Announces Positive CHMP Opinion for Zynyz®? (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

Incyte Corporation to Report Q4, 2025 Results on Feb 10, 2026

Insufficient new directors

Executive VP & Chief Medical Officer recently sold Mex$28m worth of stock

Insufficient new directors

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as First-Line Treatment for Diffuse Large B-Cell Lymphoma

Incyte Announces European Commission Approval of Minjuvi (Tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Insider recently sold Mex$10m worth of stock

Incyte Corporation Announces Resignation of Hervé Hoppenot from Board of Directors, Effective December 12, 2025

Incyte Announces New Positive Data for INCA033989, Its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented At ASH 2025

Executive VP & Chief Medical Officer recently sold Mex$43m worth of stock

Incyte Corporation Announces Executive Changes

Principal Financial Officer recently sold Mex$1.5m worth of stock

Incyte Announces Positive CHMP Opinion for Minjuvi (Tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Advisor to CEO & Director recently sold Mex$364m worth of stock

Incyte Corporation Announces More Than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

Insufficient new directors

Third quarter 2025 earnings released: EPS: US$2.17 (vs US$0.55 in 3Q 2024)

Incyte Corporation Revises Earnings Guidance for the Fiscal Year 2025

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

Eli Lilly and Company's Baricitinib Delivers Near- Complete Scalarched Hair Regrowth At One Year for Adoption of Baricitinib

Incyte Announces Phase 1 Results for Its Tgfbr2xpd-1 Bispecific Antibody in Advanced Colorectal Cancer and Kras G12d Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

Incyte Corporation to Report Q3, 2025 Results on Oct 28, 2025

Incyte Corporation Appoints Thomas Tray as Principal Financial Officer, Effective as of September 16, 2025

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer, Effective September 22, 2025

Incyte Announces Additional FDA Approval of Opzelura®? (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa

Incyte Announces Executive Changes, Effective August 25, 2025

Actuate Therapeutics, Inc. to Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Incyte Corporation Announces Departure of Christiana Stamoulis as Executive Vice President, Effective September 16, 2025

Incyte Corporation Raises Revenue Guidance for the Fiscal Year 2025

Incyte Corporation to Report Q2, 2025 Results on Jul 29, 2025

Incyte Corporation Announces Chief Executive Officer Changes

Incyte Announces Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis

Incyte Announces FDA Approval of Monjuvi®? in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Incyte Announces Phase 3 Data for it's Retifanlimab (Zynyz®?) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Insufficient new directors

Incyte Corporation Announces FDA Approval of Zynyz (Retifanlimab-Llwr) Making It the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

Insufficient new directors

Incyte Corporation, Annual General Meeting, Jun 10, 2025

Incyte Corporation Revises Revenue Guidance for the Year 2025